首页 > 医学词汇大全 > tumor lysis syndrome
tumor lysis syndrome

肿瘤

关键词肿瘤 疾病 并发症

词汇介绍

拓展阅读

解析

Tumor   英 /'tju:mə(r)/   美 /'tjʊmɚ/

释    义   n. 肿瘤;肿块;赘生物

例    句   Therefore, in early cancer, immunosuppression may not be systemic, but it may be there in the tumor itself. 因此,在癌症早期,免疫抑制可能不是全身性的,但可能存在于肿瘤局部。

 

Lysis   英 /'laɪsɪs/   美 /'laɪsɪs/

释    义   n. (生物)溶胞,溶菌;溶解,分解;(发烧等生病过程)消退

同根词   lysogenic adj. 生成细胞溶素的;溶原的;产噬的;lysozyme n. 溶解酵素;lysin n. 细胞溶解酶;lysogenicity n. 致溶解性;溶源性

例    句   Methods: The changing of platelet aggregation rate, the thrombus weight, the content of fibrinogen and the euglobulin lysis time were determined after SEF iv on rabbit and mice. 方法:采用家兔、小鼠静脉注射,并测定其血小板最大聚集率、血栓重量、纤维蛋白原含量及球蛋白溶解时间的变化。

 

Syndrome   英 /'sɪndrəʊm/   美 /'sɪndrəm/

释    义   n. [临床] 综合症状;并发症状;校验子;并发位

例    句   "We do not have future data on these girls and so we can only speculate that girls in the high risk group might develop metabolic syndrome, heart disease or type-2 diabetes, " she adds. 她补充说:“由于我们并没有这些女孩的未来的跟踪数据,所有我们仅能推测那些有高风险的女孩可能发展为代谢综合征,心脏病或2型糖尿病。”

概述

肿瘤溶解综合征(TLS)是肿瘤细胞快速溶解后细胞内各种电解质离子、核酸和蛋白质及其代谢产物大量、突然释放入血,并超过机体的自身稳定机制所引起的代谢紊乱综合征。即在恶性肿瘤(实体肿瘤和血液病)治疗过程中,可能出现的一组代谢性并发症,在部分恶性淋巴瘤和白血病患者中,甚至没有接受治疗也会发生。其发生是由于坏死肿瘤细胞崩解并有细胞内成分释放所导致,包括高钾血症、高磷血症、高尿酸血症和低钙血症,以及随之而来的急性尿酸增高性肾病和急性肾功能衰竭。TLS好发于分化差的高度恶性淋巴瘤,如伯基特淋巴瘤和T淋巴

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study复制标题

依鲁替尼联合维内托拉克斯治疗复发性/难治性慢性淋巴细胞白血病: CLARITY研究

发表时间:2019-07-11

影响因子:28.2

作者: Peter Hillmen

期刊:J. Clin. Oncol.

In early studies, venetoclax showed unexpected efficacy as monotherapy, with a proportion of patients with high-risk Chronic lymphocytic leukemia (CLL) achieving eradication of measurable residual disease (MRD) to either venetoclax monotherapy or the combination of venetoclax with rituximab. Venetoclax as a single agent is approved by the FDA for patients with CLL who have received at least one prior therapy and by the EMA for previously untreated patients with CLL in the presence of chromosome del(17p) or TP53 mutations and for patients with relapsed CLL with or without del(17p) or TP53 mutations who experience treatment failure with a BCR pathway inhibitor and CIT. Both the FDA and the EMA have approved venetoclax in combination with rituximab in patients with relapsed CLL who have received at least one prior treatment. Venetoclax is generally well tolerated but can lead to GI adverse effects (nausea and diarrhea) and neutropenia. The most common adverse events (AEs) experienced at grade 3 and higher are neutropenia, infection, and anemia. Tumor lysis syndrome (TLS) occasionally occurs in the first month of venetoclax, but with initial dosing commencing at 20 mg/d and ramping up each week to the full dose of 400 mg/d, biochemical TLS occurs in 5% of patients, and clinical TLS is rare.

译文

在早期研究中,venetoclax作为单一疗法显示出意想不到的功效,一部分患有高风险慢性淋巴细胞白血病(CLL)的患者实现了可测量的残留病(MRD)根除venetoclax单一疗法或venetoclax与利妥昔单抗的组合。 Venetoclax作为单一药物被FDA批准用于CLL患者,这些患者至少接受过一次治疗,对于既往未治疗的CLL患者,在染色体del(17p)或TP53突变存在的情况下,以及对于复发CLL患者,通过EMA有或没有del(17p)或TP53突变,经历BCR途径抑制剂和CIT治疗失败。 FDA和EMA均已批准venetoclax与利妥昔单抗联合用于复发性CLL患者,这些患者至少接受过一次治疗。 Venetoclax通常耐受性良好,但可导致胃肠道不良反应(恶心和腹泻)和中性粒细胞减少症。在3级及更高级别经历的最常见的不良事件(AEs)是中性粒细胞减少症,感染和贫血。肿瘤溶解综合征(TLS)偶尔发生在venetoclax的第一个月,但是初始剂量开始时为20 mg / d并且每周增加至400 mg / d的全剂量,5%的患者出现生化TLS,并且临床TLS很少见。